Início - FarmoLAB

Publicações do grupo nos últimos 5 anos

{slider Infection by zika virus increase angiotensin I-converting enzyme activity in mouse brain}

Lorena Andreoli, Fernando da Silva Fiorin, Hougelle Simplicio, Mirian AF Hayashi, Edgard Morya. Psychiatric Animal Models. Biochimie. 2024 Oct 31. Manuscript JoVE67005R2.

Jove accepted 2024

{slider Infection by zika virus increase angiotensin I-converting enzyme activity in mouse brain}

Oyadomari WY, Christoff RR, Nani JV, Rabello T, Oliveira V, Higa LM, Garcez PP, Hayashi MAF. Infection by zika virus increase angiotensin I-converting enzyme activity in mouse brain. Biochimie. 2024 Jul 2:S0300-9084(24)00160-3. doi: 10.1016/j.biochi.2024.07.001.

Biochimie 2024 ACE in ZIKV

{slider Embryonic origin of two ASD subtypes of social symptom severity: the larger the brain cortical organoid size, the more severe the social symptoms}

Courchesne E, Taluja V, Nazari S, Aamodt CM, Pierce K, Duan K, Stophaeros S, Lopez L, Barnes CC, Troxel J, Campbell K, Wang T, Hoekzema K, Eichler EE, Nani JV, Pontes W, Sanchez SS, Lombardo MV, de Souza JS, Hayashi MAF, Muotri AR. Embryonic origin of two ASD subtypes of social symptom severity: the larger the brain cortical organoid size, the more severe the social symptoms. Mol Autism. 2024 May 25;15(1):22. doi: 10.1186/s13229-024-00602-8.

Eric BCO

{slider Sodium nitroprusside as an adjunctive treatment for schizophrenia reduces the Ndel1 oligopeptidase activity}

Nani JV, Ushirohira JM, Bradshaw NJ, Machado-de-Sousa JP, Hallak JEC, Hayashi MAF. Sodium nitroprusside as an adjunctive treatment for schizophrenia reduces the Ndel1 oligopeptidase activity. Braz J Psychiatry. 2023 Nov 23. doi: 10.47626/1516-4446-2023-3315. doi: 10.47626/1516-4446-2023-3315. Online ahead of print.

sNP Ndel1

{slider Identification of an ex vivo inhibitor of the schizophrenia biomarker Ndel1 by high throughput screening}

Nani JV, Coelho C, Oyadomari WY, Santiago TC, Machado MM, Christoff RR, Garcez PP, Oliveira V, Würtele M, Hayashi MAF. EIdentification of an ex vivo inhibitor of the schizophrenia biomarker Ndel1 by high throughput screening. Biochem Pharmacol. 2023 Oct 9;217:115841. https://doi.org/10.1016/j.bcp.2023.115841

Biochem Pharm 2023

{slider Evaluation of tumor growth remission in a murine model for subcutaneous solid tumors – Benefits of associating the antitumor agent crotamine with mesoporous nanosilica particles to achieve improved dosing frequency and efficacy.}

Oyadomari WY, Anthero GL, Silva MRA, Porta LC, Oliveira V, Reid PF, Sant'Anna OA, Alves WA, Nani JV, Hayashi MAF. Evaluation of tumor growth remission in a murine model for subcutaneous solid tumors – Benefits of associating the antitumor agent crotamine with mesoporous nanosilica particles to achieve improved dosing frequency and efficacy. Int. J. Pharm. 2023 646(5), 123420. https://doi.org/10.1016/j.ijpharm.2023.123420

Oyadomari IJP 2023

{slider Euthymic and depressed bipolar patients are characterized by different RNA editing patterns in blood}

Hayashi MAF, Salvetat N, Cayzac C, Checa-Robles FJ, Dubuc B, Mereuze S, Nani JV, Molina F, Brietske E, Weissmann D. Euthymic and depressed bipolar patients are characterized by different RNA editing patterns in blood. Psychiatry Res. 2023 Oct;328:115422. https://doi.org/10.1016/j.psychres.2023.115422.

Dinah et al 2023

{slider Assessing the role of Ndel1 oligopeptidase activity in congenital Zika syndrome: Potential predictor of congenital syndrome endophenotype and treatment response}

Christoff RR, Nani JV, Lessa G, Rabello T, Rossi AD, Krenn V, Higa LM, Tanuri A, Garcez PP, Hayashi MAF. Assessing the role of Ndel1 oligopeptidase activity in congenital Zika syndrome: Potential predictor of congenital syndrome endophenotype and treatment response. J Neurochem. 2023 Aug;166(4):763-776. doi: 10.1111/jnc.15918.

Christoff et al 2023

Zika virus 2023

{slider [18F]F-FDG and [11C]PK11195 PET imaging in the evaluation of brown adipose tissue - effects of cold and pharmacological stimuli and their association with crotamine intake in a male mouse model}

Daniele de Paula Faria, Joana D'Arc Campeiro, Mara de Souza Junqueira, Caroline Cristiano Real, Fabio Luiz Navarro Marques, Mirian Akemi Furuie Hayashi, Marcelo Tatit Sapienza. [18F]F-FDG and [11C]PK11195 PET imaging in the evaluation of brown adipose tissue - effects of cold and pharmacological stimuli and their association with crotamine intake in a male mouse model. Nucl Med Biol. 2023 Jun 17;122-123:108362. doi: 10.1016/j.nucmedbio.2023.108362

{slider Crotamine/siRNA Nanocomplexes for Functional Downregulation of Syndecan-1 in Renal Proximal Tubular Epithelial Cells}

Joana D’Arc Campeiro, Wendy A. Dam, Mirian A. F. Hayashi, and Jacob van den Born. Crotamine/siRNA Nanocomplexes for Functional Downregulation of Syndecan-1 in Renal Proximal Tubular Epithelial Cells. 2023 May 23;15(6):1576. https://doi.org/10.3390/pharmaceutics15061576.

jaap

Campeiro et al 2 23

{slider Prolyl oligopeptidase activity (POP) in early stage and medicated schizophrenia and in an animal model for schizophrenia study: in vivo effects of psychopharmacological substances on enzyme activity}

Lucas A.N. Marins, Benjamín Rodríguez, João V. Nani, Vitor Oliveira Ary Gadelha, Mirian A.F. Hayashi. Prolyl oligopeptidase activity (POP) in early stage and medicated schizophrenia and in an animal model for schizophrenia study: in vivo effects of psychopharmacological substances on enzyme activity. Brain Disorders 10 (2023) 100075. doi: 10.1016/j.dscb.2023.100075.

POP

{slider Aberrant phase separation is a common killing strategy of positively charged peptides in biology and human disease}

Boeynaems S, Ma XR, Yeong V, Ginell GM, Chen JH, Blum JA, Nakayama L, Sanyal A, Briner A, Van Haver D, Pauwels J, Ekman A, Schmidt HB, Sundararajan K, Porta L, Lasker K, Larabell C, Hayashi MAF, Kundaje A, Impens F, Obermeyer A, Holehouse AS, Gitler AD.Aberrant phase separation is a common killing strategy of positively charged peptides in biology and human disease. bioRxiv. 2023 Mar 9:2023.03.09.531820. doi: 10.1101/2023.03.09.531820.

steven B

{slider Angiotensin Converting Enzymes as druggable features of psychiatric and neurodegenerative disorders}

Santiago TC, Parra L, Nani JV, Fidalgo TM, Bradshaw NJ, Hayashi MAF.. Angiotensin Converting Enzymes as druggable features of psychiatric and neurodegenerative disorders. J Neurochem. 2023 Jul;166(2):138-155.doi: 10.1111/jnc.15806.

review Thays

graphical Thays review

{slider ¹H NMR Metabolomics and Lipidomics To Monitor Positive Responses in Children with Autism Spectrum Disorder Following a Guided Parental Intervention: A Pilot Study}

Banny Silva Barbosa Correia, João Guilherme de Moraes Pontes, João Victor Silva Nani, Fabian Villalta, Natalia Cristina Mor, Daniela Bordini, Décio Brunoni, Helena Brentani, Jair Jesus Mari, Mirian A. F. Hayashi*, and Ljubica Tasic*. 1H NMR Metabolomics and Lipidomics To Monitor Positive Responses in Children with Autism Spectrum Disorder Following a Guided Parental Intervention: A Pilot Study. ACS Chem Neurosci. 2023 Mar 15;14(6):1137-1145. doi: 10.1021/acschemneuro.2c00735.

lipidomic autims

lipidomic autism2

{slider Doderlin: Isolation and Characterization of a Broad-Spectrum Antimicrobial Peptide from Lactobacillus acidophilus}

Bruna S.da Silva, AndreaDíaz-Roa, Erica S.Yamane, Mirian A.F.Hayashi, Pedro Ismael da Silva Junior. Doderlin: Isolation and Characterization of a Broad-Spectrum Antimicrobial Peptide from Lactobacillus acidophilus. Research in Microbiology 174 (2023) 103995. https://doi.org/10.1016/j.resmic.2022.103995.

doderlin

{slider Targeting Ca²⁺ and Mitochondrial Homeostasis by Antipsychotic Thioridazine in Leukemia Cells}

Vivian W. R. Moraes, Vivian Matsukura dos Santos, Eloah R. Suarez, Leticia S. Ferraz, Rayssa M. Lopes, Giuliana P. Mognol, Joana D. Campeiro, João Agostinho Machado-Neto, Fabio D. Nascimento, Mirian A.F. Hayashi, Ivarne L.S. Tersariol, Donald D. Newmeyer, Tiago Rodrigues. Targeting Ca²⁺ and Mitochondrial Homeostasis by Antipsychotic Thioridazine in Leukemia Cells. Life 2022;12:1477. https://doi.org/10.3390/life12101477.

Tiago

{slider Brief reports unraveling the correlation among neurodevelopmental and inflammatory biomarkers in patients with chronic schizophrenia}

Nani JV, Almeida PGC, Noto C, Bressan RA, Brietzke E, Hayashi MAF. BRIEF REPORTS UNRAVELING THE CORRELATION AMONG NEURODEVELOPMENTAL AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA. Nord J Psychiatry. 2022 Oct;76(7):559-564. doi: 10.1080/08039488.2021.2023217.

Nordic J Psych

Nordic J Psychiatry Nani

{slider Crotamine trafficking dynamic in Plasmodium falciparum-infected erythrocytes: pharmacological inhibitors, parasite cycle and incubation time influences in uptake}

El Chamy Maluf S, Hayashi MAF, Campeiro JD, Oliveira EB, Gazarini ML, Carmona AK. Crotamine trafficking dynamic in Plasmodium falciparum-infected erythrocytes: pharmacological inhibitors, parasite cycle and incubation time influences in uptake. Toxicon. 202;208:47-52. doi: 10.1016/j.toxicon.2022.01.006.

Toxicon graph abstrac v1

{slider Doderlin: Isolation and Characterization of a Broad-Spectrum Antimicrobial Peptide from Lactobacillus acidophilus}

Bruna S. da Silva, Andrea Diaz-Roa, Erica S. Yamane, Mirian A.F. Hayashi, Pedro Ismael Silva Junior. Doderlin: Isolation and Characterization of a Broad-Spectrum Antimicrobial Peptide from Lactobacillus acidophilus. bioRxiv 2022.01.19.476933; doi: https://doi.org/10.1101/2022.01.19.476933

biorvx Pedro

{slider Revisting the potential of South American rattlesnake Crotalus durissus terrificus toxins as therapeutic, theranostic and/or biotechnological agents}

Hayashi MAF, Campeiro JD, Yonamine CM. Revisting the potential of South American rattlesnake Crotalus durissus terrificus toxins as therapeutic, theranostic and/or biotechnological agents. Toxicon. 2022 Jan 30;206:1-13.doi: https://doi.org/10.1016/j.toxicon.2021.12.005

toxicon 2021

{slider A native cell-penetrating peptide (CPP) from rattlesnake with therapeutic and theranostic properties}

Porta LC, Campeiro JD, Hayashi MAF. A Native CPP from Rattlesnake with Therapeutic and Theranostic Properties. Methods Mol Biol. 2022;2383:91-104. doi: 10.1007/978-1-0716-1752-6_6.

CPP Ulo Langel

Bolsa de Pós-doutorado FAPESP (PD-BR) em Neurofarmacologia Molecular e Celular

cartaz vaga PD

Bolsa de Pós-doutorado em Neurofarmacologia Molecular e Celular.

O Laboratório de Neurofarmacologia Molecular [https://farmolab.unifesp.br/] do Departamento de Farmacologia da Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP) tem 2 (duas) bolsa de pós-doutorado aberta para desenvolver o projeto: Estudo dos mecanismos moleculares e celulares em transtornos mentais: estudos clínicos e modelos animais”. O prazo de inscrição termina em 15 de dezembro de 2024.

O projeto será supervisionado pelos Profs. Drs. Mirian Hayashi e/ou Fábio Cardoso Cruz, e tem como objetivo identificar e caracterizar as alterações bioquímicas/moleculares e/ou celulares poderiam auxiliar na precisão do diagnóstico, e também no melhor entendimento da neurobiologia envolvida nos transtornos mentais, possibilitando assim, a possível identificação de potenciais novos alvos para o desenvolvimento de fármacos inovadores, que possibilitem o tratamento mais efetivo dos sintomas, ou até mesmo a sua cura e/ou a sua possível prevenção.

O(A) candidato(a) deverá ter habilidades para trabalhar em equipe, iniciativa e criatividade na resolução de problemas. A posição exige proatividade frente a desafios científicos.

O(A) candidato(a) selecionado(a) deverá ter doutorado com resultados relevantes em seu currículo e com experiência em técnicas ou áreas correlatas. A experiência prévia na execução e análise de experimentos moleculares e celulares relacionados ao uso de animais de experimentação (camundongos e/ou ratos) é desejável. Além disso, o candidato deve ter familiaridade com o uso de vetores virais e animais transgênicos.

Requisitos

a) Doutorado em Bioquímica/Farmacologia/Fisiologia/Psicobiologia ou áreas ou afins;

b) Produção científica significativa em periódicos indexados;

c) Fluência em inglês;

d) Motivação e capacidade de trabalho em equipe.

e) Possibilidade de inicio imediato.

Documentos

a) Carta de apresentação e motivação;

b) Curriculum Lattes atualizado e o link para MyResearchID ou ORCID;

c) Cópia do certificado de doutorado;

d) Duas cartas de recomendação que ateste que o(a) candidato(a) apresenta os requisistos exigidos.

Inscrições

A inscrição deve ser feita via e-mail, enviando os documentos acima, para a Profa. Dra. Mirian Hayashi (mhayashi@unifesp.br). A seleção será realizada pela análise do currículo lattes, cartas de recomendação e será realizada uma entrevista (presencial ou online). Todos os documentos devem ser enviados até 15 de dezembro de 2024. O resultado do processo de seleção será divulgado logo em seguida, por correspondência eletrônica.

Outras Informações

É exigida dedicação integral ao projeto de pesquisa e o bolsista não pode ter emprego formal ou informal durante o período. Mais informações sobre esse tipo de bolsa: http://www.fapesp.br/270.

Mais informações sobre a vaga: www.fapesp.br/oportunidades/2849.

A vaga está aberta a brasileiros(as) e estrangeiros(as). O(A) selecionado(a) receberá Bolsa de Pós-Doutorado da FAPESP no valor de R$ 12.000,00 mensais e Reserva Técnica equivalente a 10% do valor anual da bolsa para atender a despesas imprevistas e diretamente relacionadas à atividade de pesquisa.Caso o bolsista de PD resida em domicílio fora da cidade na qual se localiza a instituição-sede da pesquisa e precise se mudar, poderá ter direito a um auxílio-instalação. Mais informações sobre a Bolsa de Pós-Doutorado da FAPESP estão disponíveis em www.fapesp.br/bolsas/pd.

Outras vagas de bolsas, em diversas áreas do conhecimento, estão no site FAPESP-Oportunidades, em www.fapesp.br/oportunidades.

Seminário THE ROLE OF BIOMOLECULAR CONDENSATES IN BIOLOGY AND DISEASE

On March 25^th, 2024 at 4 pm

Speaker: Professor Steven Boeynaems, Assistant Professor in Molecular & Human Genetics; Baylor College of Medicine - Texas Children's Hospital; Jan and Dan Duncan Neurological Research Institute, Houston, TX, USA

Local: Anfiteatro INFAR (R 3 de maio, 100) , Escola Paulista de Medicina - UNIFESP

seminar Steven 2024

Speaker further information:
The overall focus of our lab is to understand one of the most basic questions in biology: how do cells perceive and deal with stress? Stress is a universal feature of all cellular Life. Whether it concerns abiotic (e.g., temperature) or biotic (e.g., viral infection) stress, cells/organisms need to adapt to their ever-changing environment. Protein aggregation is a hallmark of a stressed cell, so how do cells protect themselves? It is becoming increasingly clear that cells undergo broad (reversible) spatial and biophysical rearrangements of their entire proteome in times of stress, yet the regulatory and organizational principles remain almost completely unresolved. Biomolecular condensates (BMCs) have emerged as key stress-responsive compartments, and our work has indeed shown that such assemblies allow cells to sense and respond to stress.

Protein aggregation and the stress response are intimately tied to human disease. They span a large range - from age-related stresses or exposure to environmental/physical stresses in neurodegenerative disease, the cellular stress caused by hypoxia and chemotherapy in the tumor microenvironment to the corruption of the host proteostatic machinery in infectious disease. Stress and the associated responses modulate the onset and progression of virtually every human disease. It therefore may come as no surprise that defects in BMCs are associated with several human diseases and the aging process. Yet, we still have a very limited understanding whether such BMC alterations are adaptive or actually driving dysfunction, and whether we can drug them. Our lab addresses this open question by using a multidisciplinary approach—spanning biophysics to in vivo modelling and drug screening—combined with orthogonal model systems and a synthetic biology tool kit to untangle how the biophysical stress response is regulated and to engineer new tools to therapeutically target it in aging and human disease.

We mostly focus on neurodegenerative diseases and brain cancer, but understand that the same molecular processes underlying these conditions are not exclusively limited to humans. Indeed, evolution has already found solutions to many of the problems we face in human medicine today. For example, while the aging human brain is incredibly susceptible to protein aggregation, other organisms seem to defy the biological limits of life and are able to maintain proteostasis in the harshest of environments. It is therefore that we are teaming up with collaborators from around the world to study stress-tolerant organisms to understand the molecular underpinnings of their resilience. Figuring out how these organisms prevent proteins from aggregating will highlight new strategies to boost proteostasis in protein aggregation diseases. In all, a multi-model and evolution-inspired approach forms the backbone of our lab. By repurposing Nature’s ingenuity, we develop innovative bio-synthetic and -mimetic tools and drugs to combat disease.

Specific areas of research (see also: Lab page.)